IBA experts will also demonstrate online adaptive treatment and provide previews to visitors to the IBA booth on multiple research projects that are currently under development.

Securing investment in proton therapy
The past five installations of the Proteus®ONE and Proteus®PLUS solutions in North America, Europe, and Asia have the first treatment room completed in less than 12 months. This allowed customers to begin providing proton therapy to their cancer patients sooner. Moreover, availability and reliability of the system allows for a fast ramp up of patients. Additionally, the open gantry design allows users to easily treat non-coplanar fields in a wide variety of indications. Consequently, Beaumont Health Cancer Center recently completed its first year of operation treating more patients than initially projected – over 100 patients in year one. Beaumont staff will share their experiences using IBA's Proteus®ONE and the benefits of its open gantry design.


Craig Stevens, MD, PhD, Chair of Radiation Oncology, Beaumont Health System, will describe his experience in adding proton therapy to the facility on Sunday, October 21st, at 12:00 PM at IBA's booth, #2033.

In addition, University of Pennsylvania, one of the earliest adopters of proton therapy with its establishment of the Roberts Proton Therapy Center, has developed and validated a model-based approach to identify patients who will benefit most from Proton Therapy. Such an approach helps identify the cancer patients who could most benefit from proton therapy. UPENN will share its model and its resulting impact on the treatment of head and neck patients.

Alexander Lin, MD, Medical Director at Roberts Proton Therapy Center, will demonstrate his patient selection model on Monday, October 22nd, at 4:00 PM at IBA's booth, #2033.

Partnering with market leaders in radiation oncology for maximum customer benefits

IBA continues to expand its collaboration with key technology partners to further integrate its proton therapy solutions with existing radiation oncology systems and equipment. At our booth, see how this provides maximum flexibility as well as new development opportunities for new and existing customers.

Earlier this year, IBA and Elekta signed an agreement to develop and offer the broadest single platform for use across all radiation treatment modalities. IBA and Elekta are developing new functionalities specific to proton therapy treatment in Elekta's Monaco® treatment planning system (TPS) and enhancing MOSAIQ® Elekta's industry-leading patient-centric oncology information system (OIS) with the goal to enable clinical pathway-driven adaptive particle therapy. This will offer a seamless experience across modalities for comprehensive radiotherapy departments and further improve patient care.

Rad Oncology Homepage